STML - ステムライン・セラピュ―ティクス (Stemline Therapeutics Inc.)


   Why Stemline Therapeutics (STML) Might Surprise This Earnings Season  2020/05/14 13:33:00 Zacks Investment Research
Stemline Therapeutics (STML) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
   Stemline Therapeutics To Go Private In $667M Transaction  2020/05/04 14:16:44 Benzinga
The New York-based oncology-focused, commercial-stage biopharma Stemline Therapeutics Inc (NASDAQ: STML ) ringed in merger Monday with a go-private deal valued at up to $667 million. Stemline said it has entered a definitive agreement to be bought by privately held Italian pharma and diagnostic company Menarini Group. The Stemline Deal Terms The deal terms call for Menarini commencing a tender offer for all outstanding shares of Stemline for a potential consideration of $12.50 per share — $11.50 in upfront cash payment and one non-tradeable Contingent Value Right, or CVR. The CVR will give the holder the right to receive an additional $1 per share in cash upon completion of the first sale … Full story available on
   Stock Alert: Stemline Stock Climbs 153% In Premarket On Acquisition News  2020/05/04 08:56:00 RTT News
Biopharmaceutical company Stemline Therapeutics Inc. (STML) is currently trading at $12.02, up $7.27 or 153.05% in the pre-market session. The stock has been trading between $3.
   Will Stemline Therapeutics (STML) Report Negative Q1 Earnings? What You Should Know  2020/05/01 16:30:34 Zacks Investment Research
Stemline Therapeutics (STML) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy  2020/02/27 12:35:07 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 26.) Co-Diagnostics Inc (NASDAQ: CODX ) Fate Therapeutics Inc (NASDAQ: FATE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Inspire Medical Systems Inc (NYSE: INSP ) (reacted to fourth-quarter results) Mersana Therapeutics Inc (NASDAQ: MRSN ) Moderna Inc (NASDAQ: MRNA ) Nevro Corp (NYSE: NVRO ) (announced fourth-quarter results) Oyster Point Pharma Inc (NASDAQ: OYST ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Revolution Medicines Inc (NASDAQ: RVMD ) Vir Biotechnology Inc (NASDAQ: VIR ) (announced a collaboration with WuXi Biologics for the development of antibodies to treat COVID-19) Down In The Dumps (Biotech stocks that hit 52-week lows Feb. 26.) ABIOMED, Inc. (NASDAQ: ABMD ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Acorda Therapeutics Inc (NASDAQ: ACOR ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Auris Medical Holding Ltd (NASDAQ: EARS )(announced publication of results of a study showing anti-epileptic and anti-convulsive activity of betahistine in a mouse model) Blueprint Medicines Corp (NASDAQ: BPMC ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Curis, Inc. (NASDAQ: CRIS ) Enochian Biosciences Inc (NASDAQ: ENOB ) Galectin Therapeutics Inc.